Wyeth Receives Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine
The US Food and Drug Administration (FDA) has granted Fast Track designation to Wyeth Pharmaceuticals’ (Collegeville, PA) investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers.
The US Food and Drug Administration (FDA) has granted Fast Track designation to Wyeth Pharmaceuticals’ (Collegeville, PA) investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is seeking a pediatric indication for active immunization against invasive pneumococcal disease (IPD) and otitis media caused by serotypes included in the vaccine. The vaccine includes six new serotypes (1, 3, 5, 6A, 7F, and 19A) in addition to the seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) included in Prevnar, pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein), also known as PCV7.
Fast Track designation is designed to facilitate review of products that address serious or potentially life-threatening conditions for which there is an unmet medical need. With Fast Track designation, Wyeth plans to submit the biologics license application on a rolling basis as sections of the application are completed, enabling the FDA to begin review sooner.
Wyeth expects to complete its US filing for pediatric use of the vaccine in the first quarter of 2009. The company is also exploring opportunities to accelerate the timing of pediatric filings of the vaccine in the rest of the world from its current target of the first quarter of 2009. Wyeth’s investigational 13-valent pneumococcal conjugate vaccine is being studied in Phase 3 global clinical trials in both infants and adults.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
